Latest From Alector Inc.
There have been eight US biopharma IPOs in 2019, but only three are trading above their launch price – a big change from just three days ago.
Public Company Edition: Four more IPOs in the US bring the year's total to seven – all in February. Also, Agenus launched its digital security offering, MacroGenics leads recent follow-on offerings and four companies reveal new job cuts.
IPO market is expected to pick up in 2019 after a slow start, due in part to the government shutdown, and VC investment appears steady, but M&A outlook remains mixed.
Public Company Edition: Grossing $276m, Gossamer would have been the third-largest biopharma IPO in the US if it had launched last year. Also, recent public company financings include debt and follow-on offerings; and two more firms cut jobs – Capricor and Seres.
Drug Discovery Tools
- Drug Discovery Tools
- Therapeutic Areas
- Neurology, Nervous System
- North America
- Parent & Subsidiaries
- Alector Inc.
- Senior Management
Arnon Rosenthal, PhD, Pres. & CEO
Robert Paul, MD, PhD, CMO
Robert King, PhD, Chief Dev. Officer
Sabah Oney, PhD, CBO
Calvin Yu, Head, Fin.
- Contact Info
Phone: (415) 231-5660
151 Oyster Point Blvd.
South San Francisco, CA 94080
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.